{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:00:42Z","timestamp":1790686842046,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Hospitals Authority Youth Programme","award":["QML 20181207"],"award-info":[{"award-number":["QML 20181207"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872676"],"award-info":[{"award-number":["81872676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipality Natural Science Foundation","award":["7192063"],"award-info":[{"award-number":["7192063"]}]},{"name":"Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals","award":["XTYB201806"],"award-info":[{"award-number":["XTYB201806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Carbapenems are \u03b2-lactam antibiotics which are used to treat severe infections caused by multidrug resistant <jats:italic>Enterobacteriacea<\/jats:italic>. The recent emergence and rapid spread of <jats:italic>Enterobacteriaceae<\/jats:italic> resistant to carbapenems is a global concern. We undertook a systematic review of the antibiotic susceptibility and genotypic characteristics of carbapenem-resistant <jats:italic>Enterobacteriaceae<\/jats:italic> in Chinese neonates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systematic literature reviews were conducted (PubMed\/Medline, Embase, Wanfang medical online databases, China National Knowledge Infrastructure (CNKI) database) regarding sepsis caused by carbapenem-resistant <jats:italic>Enterobacteriaceae<\/jats:italic> in Chinese neonates aged 0-30\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>17 studies were identified. Eleven patients in the six studies reported the source of infection. Ten patients (10\/11, 90.9%) were hospital-acquired infections. Genotypic data were available for 21 isolates in 11 studies (20\u00a0<jats:italic>K. pneumoniae<\/jats:italic>, 1 <jats:italic>E. coli<\/jats:italic>). NDM-1 was the most frequently reported carbapenem-resistant genotype (81.0%, 17\/21). Carbapenem-resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> and <jats:italic>Escherichia coli<\/jats:italic> were resistant to many antibiotic classes with the exception of colistin and fosfomycin. Sequence type 105 (ST105) was the most commonly reported <jats:italic>K. pneumoniae<\/jats:italic> ST type (30.8%; 4\/13), which was from the same hospital in Western China. ST17 and ST20 were the second and third most common <jats:italic>K. pneumoniae<\/jats:italic> ST type, 23.1% (3\/13) and 15.4% (2\/13) respectively. The three strains of ST17 are all from the same hospital in central China. The two strains of ST20, although not from the same hospital, belong to the eastern part of China.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>Klebsiella pneumoniae<\/jats:italic> with the NDM-1 genotype was the leading cause of neonatal carbapenem resistant sepsis in China. Hospital acquired infection is the main source of carbapenem resistant sepsis. There is currently no licenced antibiotic regimen available to treat such an infection in China. Improved surveillance, controlling nosocomial infection and the rational use of antibiotics are the key factors to prevent and reduce its spread.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-019-0334-9","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T16:02:49Z","timestamp":1573747369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China"],"prefix":"10.1186","volume":"18","author":[{"given":"Yijun","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-7255","authenticated-orcid":false,"given":"Yajuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfen","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"334_CR1","doi-asserted-by":"crossref","unstructured":"Li L, Shefali O, Daniel H, et al. Global, regional, and national causes of child mortality in 2000\u201313, with projections to inform post-2015 priorities: an updated systematic analysis. 2015. p. 430-440.","DOI":"10.1016\/S0140-6736(14)61698-6"},{"issue":"3","key":"334_CR2","doi-asserted-by":"publisher","first-page":"F249","DOI":"10.1136\/archdischild-2012-301767","volume":"98","author":"A Al-Taiar","year":"2013","unstructured":"Al-Taiar A, Hammoud MS, Cuiqing L, et al. Neonatal infections in China, Malaysia, Hong Kong and Thailand. Arch Dis Child Fetal Neonatal Ed. 2013;98(3):F249\u201355.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"10014","key":"334_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","volume":"387","author":"R Laxminarayan","year":"2016","unstructured":"Laxminarayan R, Matsoso P, Pant S, Brower C, R\u00f8ttingen JA, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387(10014):168\u201375.","journal-title":"Lancet."},{"key":"334_CR4","first-page":"895","volume":"7","author":"CR Lee","year":"2016","unstructured":"Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895.","journal-title":"Front Microbiol."},{"issue":"6","key":"334_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/cid\/cis543","volume":"55","author":"LK Logan","year":"2012","unstructured":"Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis. 2012;55(6):852\u20139.","journal-title":"Clin Infect Dis"},{"key":"334_CR6","first-page":"241","volume":"2018","author":"F Hu","year":"2017","unstructured":"Hu F, Guo Y, Zhu D, Wang F, Jiang X, Xu Y. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET surveillance program. Chin J Infect Chemother. 2017;2018:241\u201351.","journal-title":"Chin J Infect Chemother."},{"key":"334_CR7","unstructured":"Clinical and Laboratory Standards Institute. M100-S25. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement [S]. Wayne: CLSI. 2015."},{"issue":"12","key":"334_CR8","first-page":"897","volume":"41","author":"Group CM","year":"2003","unstructured":"Group CM. Protocol for diagnosis and treatment of neonatal septicemia. Chin J Pediatr. 2003;41(12):897\u20139.","journal-title":"Chin J Pediatr."},{"key":"334_CR9","unstructured":"FDA. General Clinical Pharmacology Considerations for Pediatric studies for Drugs and Biological products. 2014."},{"key":"334_CR10","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"334_CR11","first-page":"297","volume":"8","author":"MT Zmarlicka","year":"2015","unstructured":"Zmarlicka MT, Nailor MD, Nicolau DP. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist. 2015;8:297\u2013309.","journal-title":"Infect Drug Resist."},{"issue":"1","key":"334_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/INF.0000000000000471","volume":"34","author":"PS Pannaraj","year":"2015","unstructured":"Pannaraj PS, Bard JD, Cerini C, Weissman SJ. Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. Pediatr Infect Dis J. 2015;34(1):11\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"334_CR13","volume-title":"Essential medicines and health products: Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"WHO","year":"2018","unstructured":"WHO. Essential medicines and health products: Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: WHO; 2018."},{"issue":"9","key":"334_CR14","doi-asserted-by":"publisher","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","volume":"61","author":"MA Hackel","year":"2017","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from north America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61(9):e00093.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"334_CR15","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.15190\/d.2018.1","volume":"6","author":"S Andrei","year":"2018","unstructured":"Andrei S, Valeanu L, Chirvasuta R, Stefan M-G. New FDA approved antibacterial drugs: 2015\u20132017. Discoveries. 2018;6(1):e81.","journal-title":"Discoveries."},{"issue":"10","key":"334_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","volume":"24","author":"L Papst","year":"2018","unstructured":"Papst L, Beovi\u0107 B, Pulcini C, Durante-Mangoni E, Rodr\u00edguez-Ba\u00f1o J, Kaye KS. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"334_CR17","first-page":"415","volume":"20","author":"R Thomas","year":"2019","unstructured":"Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. 2019;20(4):415\u201322.","journal-title":"The use of polymyxins to treat carbapenem resistant infections in neonates and children."}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-019-0334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-019-0334-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-019-0334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:17:56Z","timestamp":1605226676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-019-0334-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1186\/s12941-019-0334-9","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper is a systematic review, so ethical approval and consent is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}